CoChat

EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency

Styles, Christine T., Bazot, Quentin, Parker, Gillian A., White, Robert E., Paschos, Kostas, Allday, Martin J. · 2017 · PLOS Biology
Cited by 78

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pbio.2001992

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • The Polycomb complex PRC2 and its mark in life

    Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · cited 9×

    “These data, and those described in many other reports, are consistent with EBNA3A and EBNA3C binding to regulatory elements, followed by the removal of activation-associated histone marks (e.g., H3/H4KAc), concomitant chromosomal conformational changes, and finally further covalent histone modifications by polycomb pr…”
    BackgroundInfluential
  • EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

    McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · cited 9×

    “These data, and those described in many other reports, are consistent with EBNA3A and EBNA3C binding to regulatory elements, followed by the removal of activation-associated histone marks (e.g., H3/H4KAc), concomitant chromosomal conformational changes, and finally further covalent histone modifications by polycomb pr…”
    MethodInfluential

Show all 2 references

Research works printed but not linked: 60

  1. JL Kutok, 2006, Spectrum of Epstein-Barr virus-associated diseases, Annu Rev Pathol, 1, 375, 10.1146/annurev.pathol.1.110304.100209 · DOI · Paper page
  2. LS Young, 2004, Epstein-Barr virus: 40 years on, Nat Rev Cancer, 4, 757, 10.1038/nrc1452 · DOI · Paper page
  3. LS Young, 2016, Epstein-Barr virus: more than 50 years old and still providing surprises, Nat Rev Cancer, 16, 789, 10.1038/nrc.2016.92 · DOI · Paper page
  4. E Forte, 2011, The role of microRNAs in Epstein-Barr virus latency and lytic reactivation, Microbes Infect, 13, 1156, 10.1016/j.micinf.2011.07.007 · DOI
  5. JE Roughan, 2009, The intersection of Epstein-Barr virus with the germinal center, J Virol, 83, 3968, 10.1128/JVI.02609-08 · doi:10.1128/jvi.02609-08
  6. DA Thorley-Lawson, 2013, The pathogenesis of Epstein-Barr virus persistent infection, Curr Opin Virol, 3, 227, 10.1016/j.coviro.2013.04.005 · DOI · Paper page
  7. F Heuts, 2014, T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized mice, J Virol, 88, 3235, 10.1128/JVI.02885-13 · DOI
  8. N Nagy, 2012, Soluble factors produced by activated CD4+ T cells modulate EBV latency, Proc Natl Acad Sci U S A, 109, 1512, 10.1073/pnas.1120587109 · doi:10.1073/pnas.1120587109
  9. LL Laichalk, 2005, Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo, J Virol, 79, 1296, 10.1128/JVI.79.2.1296-1307.2005 · DOI · Paper page
  10. MJ Allday, 2015, The EBNA3 family: Two oncoproteins and a tumour suppressor that are central to the biology of EBV in B cells, Curr Top Microbiol Immunol, 391, 61
  11. RE White, 2010, Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification, PLoS ONE, 5, e13979, 10.1371/journal.pone.0013979 · DOI
  12. JS Kalchschmidt, 2016, EBNA3C directs recruitment of RBPJ (CBF1) to chromatin during the process of gene repression in EBV infected B cells, PLoS Pathog, 12, e1005383, 10.1371/journal.ppat.1005383 · DOI
  13. S Jiang, 2014, Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A, Proc Natl Acad Sci U S A, 111, 421, 10.1073/pnas.1321704111 · DOI
  14. SC Schmidt, 2015, Epstein-Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes, Proc Natl Acad Sci U S A, 112, 554, 10.1073/pnas.1422580112 · DOI
  15. K Paschos, 2016, Core binding factor (CBF) is required for Epstein-Barr virus EBNA3 proteins to regulate target gene expression, Nucleic Acids Res
  16. MJ McClellan, 2013, Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming, PLoS Pathog, 9, e1003636, 10.1371/journal.ppat.1003636 · DOI
  17. JS Kalchschmidt, 2016, Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells, J Exp Med, 213, 921, 10.1084/jem.20160120 · DOI
  18. CD Wood, 2016, MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs, Elife, 5
  19. Q Bazot, 2015, Epstein-Barr virus proteins EBNA3A and EBNA3C together induce expression of the oncogenic microRNA cluster miR-221/miR-222 and ablate expression of its target p57KIP2, PLoS Pathog, 11, e1005031, 10.1371/journal.ppat.1005031 · DOI
  20. MJ Allday, 2013, EBV finds a polycomb-mediated, epigenetic solution to the problem of oncogenic stress responses triggered by infection, Front Genet, 4, 212, 10.3389/fgene.2013.00212 · DOI
  21. Q Bazot, 2014, Epstein-Barr virus nuclear antigen 3A protein regulates CDKN2B transcription via interaction with MIZ-1, Nucleic Acids Res, 42, 9700, 10.1093/nar/gku697 · DOI
  22. RE White, 2012, EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors, J Clin Invest, 122, 1487, 10.1172/JCI58092 · DOI · Paper page
  23. S Gagrica, 2012, Contrasting behavior of the p18INK4c and p16INK4a tumor suppressors in both replicative and oncogene-induced senescence, Cancer Res, 72, 165, 10.1158/0008-5472.CAN-11-2552 · DOI
  24. MR Tourigny, 2002, CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells, Immunity, 17, 179, 10.1016/S1074-7613(02)00364-3 · DOI
  25. L Morse, 1997, Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6, Immunity, 6, 47, 10.1016/S1074-7613(00)80241-1 · DOI · Paper page
  26. J O'Nions, 2004, Proliferation and differentiation in isogenic populations of peripheral B cells activated by Epstein-Barr virus or T cell-derived mitogens, J Gen Virol, 85, 881, 10.1099/vir.0.19704-0 · DOI
  27. CC Goodnow, 2010, Control systems and decision making for antibody production, Nat Immunol, 11, 681, 10.1038/ni.1900 · DOI · Paper page
  28. W Shi, 2015, Transcriptional profiling of mouse B cell terminal differentiation defines a signature for antibody-secreting plasma cells, Nat Immunol, 16, 663, 10.1038/ni.3154 · DOI · Paper page
  29. SL Nutt, 2015, The generation of antibody-secreting plasma cells, Nat Rev Immunol, 15, 160, 10.1038/nri3795 · DOI · Paper page
  30. M Minnich, 2016, Multifunctional role of the transcription factor Blimp-1 in coordinating plasma cell differentiation, Nat Immunol, 17, 331, 10.1038/ni.3349 · DOI · Paper page
  31. YH Yu, 2016, Factors that regulate the generation of antibody-secreting plasma cells, Adv Immunol, 131, 61, 10.1016/bs.ai.2016.03.001 · DOI
  32. K Igarashi, 2016, Orchestration of B lymphoid cells and their inner myeloid by Bach, Curr Opin Immunol, 39, 136, 10.1016/j.coi.2016.01.012 · DOI
  33. A Wang, 2015, Epstein-Barr virus nuclear antigen 3 (EBNA3) proteins regulate EBNA2 binding to distinct RBPJ genomic sites, J Virol, 90, 2906, 10.1128/JVI.02737-15 · DOI
  34. S Nam, 2016, Essential role of interferon regulatory factor 4 (IRF4) in immune cell development, Arch Pharm Res, 39, 1548, 10.1007/s12272-016-0854-1 · DOI
  35. R Feil, 1997, Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains, Biochem Biophys Res Commun, 237, 752, 10.1006/bbrc.1997.7124 · DOI · Paper page
  36. B Chambraud, 1990, Several regions of human estrogen receptor are involved in the formation of receptor-heat shock protein 90 complexes, J Biol Chem, 265, 20686, 10.1016/S0021-9258(17)30558-6 · DOI · Paper page
  37. S Maruo, 2006, Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells, Proc Natl Acad Sci U S A, 103, 19500, 10.1073/pnas.0604919104 · DOI · Paper page
  38. L Skalska, 2010, Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP, PLoS Pathog, 6, e1000951, 10.1371/journal.ppat.1000951 · DOI · Paper page
  39. L Skalska, 2013, Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines, PLoS Pathog, 9, e1003187, 10.1371/journal.ppat.1003187 · DOI · Paper page
  40. S Maruo, 2011, Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression, Proc Natl Acad Sci U S A, 108, 1919, 10.1073/pnas.1019599108 · DOI
  41. K Paschos, 2012, BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV, Nucleic Acids Res, 40, 7233, 10.1093/nar/gks391 · DOI
  42. K Nilsson, 1970, Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient, Clin Exp Immunol, 7, 477
  43. M Hallek, 1998, Multiple myeloma: increasing evidence for a multistep transformation process, Blood, 91, 3, 10.1182/blood.V91.1.3 · DOI · Paper page
  44. H Schmidlin, 2008, Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression, Blood, 112, 1804, 10.1182/blood-2008-01-136440 · DOI · Paper page
  45. E Cubedo, 2011, PRDM1/Blimp1 downregulates expression of germinal center genes LMO2 and HGAL, FEBS J, 278, 3065, 10.1111/j.1742-4658.2011.08227.x · doi:10.1111/j.1742-4658.2011.08227.x
  46. AC Rawstron, 2006, Immunophenotyping of plasma cells, Curr Protoc Cytom, 23
  47. N Robillard, 2014, Immunophenotype of normal and myelomatous plasma-cell subsets, Front Immunol, 5, 137, 10.3389/fimmu.2014.00137 · DOI · Paper page
  48. HT Maecker, 2012, Standardizing immunophenotyping for the Human Immunology Project, Nat Rev Immunol, 12, 191, 10.1038/nri3158 · DOI · Paper page
  49. EK Deenick, 2013, Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells, J Exp Med, 210, 2739, 10.1084/jem.20130323 · DOI · Paper page
  50. S Ikeyama, 1986, Purification and characterization of IgE produced by human myeloma cell line, U266, Mol Immunol, 23, 159, 10.1016/0161-5890(86)90038-6 · doi:10.1016/0161-5890(86)90038-6
  51. PA Nikitin, 2010, An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells, Cell Host Microbe, 8, 510, 10.1016/j.chom.2010.11.004 · DOI · Paper page
  52. B Zhao, 2011, Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth, Proc Natl Acad Sci U S A, 108, 14902, 10.1073/pnas.1108892108 · DOI · Paper page
  53. H Zhou, 2015, Epstein-Barr virus oncoprotein super-enhancers control B cell growth, Cell Host Microbe, 17, 205, 10.1016/j.chom.2014.12.013 · DOI · Paper page
  54. J Mandelbaum, 2010, BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma, Cancer Cell, 18, 568, 10.1016/j.ccr.2010.10.030 · DOI · Paper page
  55. M Boi, 2015, PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas, Leuk Lymphoma, 56, 1223, 10.3109/10428194.2014.953155 · DOI
  56. S Liu, 2016, Gata3 restrains B cell proliferation and cooperates with p18INK4c to repress B cell lymphomagenesis, Oncotarget, 7, 64007, 10.18632/oncotarget.11746 · DOI
  57. Y Xia, 2016, Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma, Leukemia
  58. ML Harth-Hertle, 2013, Inactivation of intergenic enhancers by EBNA3A initiates and maintains polycomb signatures across a chromatin domain encoding CXCL10 and CXCL9, PLoS Pathog, 9, e1003638, 10.1371/journal.ppat.1003638 · DOI
  59. JA Reusch, 2015, Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters, J Virol, 89, 1731, 10.1128/JVI.02781-14 · DOI
  60. RE White, 2003, Generation and precise modification of a herpesvirus saimiri bacterial artificial chromosome demonstrates that the terminal repeats are required for both virus production and episomal persistence, J Gen Virol, 84, 3393, 10.1099/vir.0.19387-0 · doi:10.1099/vir.0.19387-0

Cited by

Metadata

Authors
Styles, C. T., Bazot, Q., Parker, G. A., White, R. E., Paschos, K., & Allday, M. J.
Venue
PLOS Biology
Published
2017-08-03
Volume
15
Issue
8
Pages
e2001992
ISSN
1545-7885
Cited by
78
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.